All In Biotech

Free tool

FAERS Monitor: Vyepti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761119 or its brand name (Vyepti, Eptinezumab-Jjmr). Reports on generic versions are filed under their own applications.

Reports

9,754

Serious

2,514

26% of reports

Hospitalization

772

Death reported

68

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2,135
  • migraine1,565
  • headache1,024
  • therapeutic response shortened602
  • nausea575
  • fatigue526
  • throat irritation384
  • drug effect less than expected383
  • dizziness382
  • pruritus343
  • nasal congestion275
  • dyspnoea229
  • hypersensitivity221
  • vomiting213
  • inappropriate schedule of product administration205

Reports by year received

View as table
YearReports
20162
20192
2020156
2021750
20221,262
20231,668
20242,246
20252,064
20261,604

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,405 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug effect less than expectedSignal38357.251.820,557
therapeutic response shortenedSignal60239.836.922,383
migraineSignal1,56535.934.352,467
throat irritationSignal38418.616.96,339
nasal congestionSignal27510.19.02,251
headacheSignal1,0243.53.31,904
drug ineffectiveSignal2,1353.53.44,052
hypersensitivitySignal2212.62.3212
inappropriate schedule of product administrationSignal2052.52.1177
pruritus3431.91.7154
dizziness3821.71.5100
nausea5751.61.4122
fatigue5261.51.378
vomiting2131.00.90
dyspnoea2290.90.84

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.